A detailed history of Jpmorgan Chase & CO transactions in Novavax Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 83,915 shares of NVAX stock, worth $1.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,915
Previous 118,291 29.06%
Holding current value
$1.14 Million
Previous $565,000 87.96%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$3.89 - $20.97 $133,722 - $720,864
-34,376 Reduced 29.06%
83,915 $1.06 Million
Q1 2024

May 10, 2024

SELL
$3.76 - $6.02 $157,630 - $252,376
-41,923 Reduced 26.17%
118,291 $565,000
Q4 2023

Feb 12, 2024

BUY
$4.8 - $7.67 $123,297 - $197,019
25,687 Added 19.09%
160,214 $769,000
Q3 2023

Nov 14, 2023

SELL
$6.81 - $9.74 $21,328 - $30,505
-3,132 Reduced 2.28%
134,527 $973,000
Q2 2023

Aug 11, 2023

BUY
$6.67 - $9.52 $309,394 - $441,594
46,386 Added 50.82%
137,659 $1.02 Million
Q1 2023

May 18, 2023

BUY
$5.76 - $12.48 $276,779 - $599,688
48,052 Added 111.18%
91,273 $632,000
Q1 2023

May 11, 2023

SELL
$5.76 - $12.48 $11,813 - $25,596
-2,051 Reduced 4.53%
43,221 $299,000
Q4 2022

Feb 13, 2023

SELL
$8.86 - $25.04 $59,521 - $168,218
-6,718 Reduced 12.92%
45,272 $465,000
Q3 2022

Nov 14, 2022

SELL
$18.2 - $76.12 $91,018 - $380,676
-5,001 Reduced 8.78%
51,990 $946,000
Q2 2022

Aug 11, 2022

SELL
$36.28 - $75.29 $484,156 - $1 Million
-13,345 Reduced 18.97%
56,991 $2.93 Million
Q1 2022

May 11, 2022

BUY
$69.73 - $142.9 $716,615 - $1.47 Million
10,277 Added 17.11%
70,336 $5.18 Million
Q4 2021

Feb 10, 2022

SELL
$134.56 - $217.97 $26.8 Million - $43.4 Million
-199,329 Reduced 76.85%
60,059 $8.59 Million
Q3 2021

Nov 12, 2021

BUY
$177.8 - $270.58 $46.1 Million - $70.2 Million
259,388 New
259,388 $53.8 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $1.06B
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.